APA (7th ed.) Citation

Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, & Walzer S. (2012). Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain. Dove Medical Press.

Chicago Style (17th ed.) Citation

Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, and Walzer S. Societal Savings in Patients with Advanced Non-squamous Non-small-cell Lung Cancer Receiving Bevacizumab-based Versus Non-bevacizumab-based Treatments in France, Germany, Italy, and Spain. Dove Medical Press, 2012.

MLA (9th ed.) Citation

Lister J, et al. Societal Savings in Patients with Advanced Non-squamous Non-small-cell Lung Cancer Receiving Bevacizumab-based Versus Non-bevacizumab-based Treatments in France, Germany, Italy, and Spain. Dove Medical Press, 2012.